Awakn Life Sciences Corp.: Awakn Life Sciences Signs Collaboration Agreement with University of Exeter for Upcoming Phase III Trial

Phase III Trial Will Assess Ketamine-Assisted Therapy for the Treatment of Severe Alcohol Use Disorder
Toronto, Ontario--(Newsfile Corp. - April 18, 2023) - Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB:

Related Keywords

United Kingdom ,United States ,Toronto ,Ontario ,Canada ,Exeter ,Devon ,Gordo Whittaker ,Anthony Tennyson ,Celia Morgan ,Linkedin Facebook ,National Institute For Health ,Regulatory Authority ,Care Research ,Awakn Life Sciences Corp ,National Institute Of Health ,Research Council ,University Of Exeter Uo ,Medicine Health ,Newsfile Corp ,University Of Exeter ,United Kingdom National Health Service ,Awakn Life Sciences ,Will Assess Ketamine Assisted Therapy ,Severe Alcohol Use ,Life Sciences ,Alcohol Use Disorder ,National Institute ,Medical Research Council ,Ketamine Assisted Therapy ,Innovative Licensing ,Access Pathway ,Care Excellence ,United States Securities Act ,Awakn Life ,Awakn ,Life ,Ciences ,Orp ,Signs ,Collaboration ,Agreement ,University ,Pcoming ,Hase ,Trial ,